Reports Q3 revenue $181,669, consensus $330,000. “This past quarter was an important period of progress for the Company highlighted by ColoFuture’s spectacular readout of results. Multiple novel mRNA biomarkers were identified for potential integration into our pivotal clinical trial being designed to potentially bring to market the gold-standard CRC self-administered screening test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “This fantastic milestone coupled with ColoAlert’s commercial momentum, and our product development initiatives, have us well positioned to meet our corporate growth objectives for the foreseeable future.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYNZ:
- Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
- Mainz Biomed to sell 4.17M shares at $1.20 in registered direct offering
- Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
- Mainz Biomed partners with Liquid Biosciences for colorectal screening test